The demonstration of both cancer cell-autonomous effects and anti-tumour immunity induced by enhanced IFN-signalling upon application of a highly selective PARP7 inhibitor (RBN-2397)65, led to a phase 1 clinical study (NCT04053673) of this drug for patients with advanced solid tumours. Here, TIPARP is linked to neoplasm.